Treats partial-onset seizures. ANDA 217059, held by Baxter Hlthcare Corp. Levetiracetam.
As of Nov 15, 2026, ANDA 217059 (Levetiracetam In Sodium Chloride), held by Baxter Hlthcare Corp, was first approved by FDA on Oct 2, 2023, with 1 approved supplement and 0 published complete response letters.
Levetiracetam in Sodium Chloride Injection is indicated for adjunct therapy in adults (≥16 years of age) with the following seizure types when oral administration is temporarily not feasible:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 2, 2023 | Original application | Approved | None posted |
| Levetiracetam In Sodium Chloride500MG/100ML (5MG/ML) · injectable;intravenous | Levetiracetam | Rx |
| Levetiracetam In Sodium Chloride1GM/100ML (10MG/ML) · injectable;intravenous | Levetiracetam | Rx |
| Levetiracetam In Sodium Chloride1.5GM/100ML (15MG/ML) · injectable;intravenous | Levetiracetam | Rx |
| Jul 3, 2024 | Supplement 1Labeling · Standard review | Approved | None posted |
| Oct 2, 2023 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters